Spinogenix Completes Enrollment in Phase 2 Clinical Trial of Tazbentetol for Schizophrenia Treatment

First-in-Class Synaptic Regenerative Therapy Aims to Address Positive, Negative and Cognitive Symptom Domains Oral Presentation on Interim Data Planned for Schizophrenia International Research Society (SIRS) Annual Congress   LOS ANGELES – March 11, 2026 – Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients worldwide, today…

Spinogenix Announces FRAXA Research Foundation Support for PIs Leading Phase 2b Trial of Investigational Therapy SPG601 for People with Fragile X Syndrome (FXS)

SPG601 is a first-in-class, BK-modulator with the potential to improve cognitive, emotional and sensory symptoms in FXS patients  LOS ANGELES, February X, 2026 — Spinogenix, Inc. a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics with the potential to restore synapses that could improve the lives of patients worldwide, today announced that a grant from the FRAXA…

Spinogenix Reports Evidence of Rapid, Sustained Cognitive Improvement in Alzheimer’s Patients from Phase 2a Trial of TAZBENTETOL (formerly SPG302)

Tazbentetol, a Potential First-in-Class, Oral Synaptic Regenerative Investigational Therapy, Showed a Favorable Safety Profile and Promising Benefits in Multiple Outcome Measures Subset Exhibited Significant Improvement in AD-Related Brain Activity, As Assessed by EEG LOS ANGELES, December 8, 2025 — Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives…

Spinogenix Announces World Health Organization Approval of ‘tazbentetol’ as International Non-Proprietary Name for SPG302

Tazbentetol is a First-in-Class, Synaptic Regenerative Investigation Therapy for Alzheimer’s disease, ALS, Schizophrenia and Glaucoma LOS ANGELES, December 1, 2025 — Spinogenix, Inc., a clinical-stage pharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients worldwide, today announced that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization…

Spinogenix Presents Topline Phase 2a Clinical Trial Results for SPG302, a First-in-Class ALS Treatment

The First Synaptic Regenerative Drug, SPG302, Led to Slowed Disease Progression in ALS Patients LOS ANGELES, Nov. 4, 2025 /PRNewswire/ — Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics designed to restore synapses to improve health in the lives of patients, presented initial positive topline results from its completed Phase 2a study for SPG302,…

Spinogenix to Present Complete Phase 2a Clinical Trial Results for SPG601, a First-in-Class Fragile X Syndrome Treatment, at AACAP Conference

SPG601, Granted Fast Track Designation by the FDA, Reduced Signature Changes in High-Frequency Gamma Band Activity in Fragile X Syndrome Patients, a Common Inherited Form of Intellectual Disability and Autism, and Improved Measures of Cognitive Impairment Dr. Craig Erickson, Spinogenix Chief Medical Advisor, to Receive Prestigious George Tarjan Award for Contributions in Developmental Disabilities. LOS…

Spinogenix Announces Publication of Preclinical Study Demonstrating Neuroprotective Effects of SPG302 in a Model of Glaucoma

The Study Results, Published in Experimental Eye Research journal, Found SPG302 Protected Retinal Ganglion Cells and Their Axons in the Glaucomatous Retina and Improved Retinal Function LOS ANGELES, Oct. 16, 2025 /PRNewswire/ — Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients worldwide, today announced the…

Spinogenix Announces Positive Type C Meeting with the FDA for SPG601 in Patients with Fragile X Syndrome (FXS)

Spinogenix has reached agreement with the FDA on important design elements for a Phase 2B/3 clinical trial of SPG601 for the treatment of FXS There Are No FDA-Approved Treatments for FXS, a Leading Inherited Form of Intellectual Disability and Known Cause of Autism LOS ANGELES, Sept. 2, 2025 /PRNewswire/ — Spinogenix, Inc., a clinical-stage biopharmaceutical…

Spinogenix Announces Positive First Cohort Results from Phase 2a Trial Evaluating SPG302 for Alzheimer’s Disease

SPG302, a Potential First-in-Class Synaptic Regenerative Therapy, Showed Progress in Cognitive Outcome Measures and a Favorable Safety Profile LOS ANGELES, Calif., Aug. 7, 2025 /PRNewswire/ — Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients worldwide, today announced positive results from the first cohort of its Phase 2a trial…

European Medicines Agency Grants Orphan Drug Designation to Spinogenix’s SPG601 for Treatment of Fragile X Syndrome (FXS)

FXS is a Common Inherited Form of Autism EMA Designation Offers People with FXS Throughout European Union Access to Novel Therapeutic LOS ANGELES, July 7, 2025 /PRNewswire/ — Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients worldwide, today announced that the European Medicines Agency (EMA) has granted orphan…